Core Insights - Neuronetics, Inc. is a commercial stage medical technology company focused on transforming patient lives through neurohealth therapies [1][2] - The management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [1] Company Overview - Neuronetics is a global leader in neuroscience, providing innovative treatment options for mental health conditions [2] - The company offers the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for patients with major depressive disorder (MDD) when traditional medications are ineffective [2] - NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with over 7.4 million treatments delivered and supported by the largest clinical data set for TMS treatments [2] - Neuronetics operates Greenbrook TMS Inc., which runs treatment centers across the U.S. and has provided over 1.8 million treatments to more than 55,000 patients [2] Treatment Details - The NeuroStar Advanced Therapy System is FDA-cleared for adults with MDD and as an adjunct treatment for obsessive-compulsive disorder and anxiety symptoms in adults with MDD [3] - It is also approved as a first-line adjunct treatment for adolescents aged 15-21 with MDD [3]

Transforming Lives Through NeuroHealth COMPANY PRESENTATION NASDAQ: STIM November 2025 Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. ("Neuronetics" or the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and d ...

Core Insights - Neuronetics, Inc. reported total revenue of $37.3 million for Q3 2025, reflecting an 11% adjusted pro forma growth compared to Q3 2024, and a 101% increase on an unadjusted basis [1][7] - The company generated $21.8 million in revenue from Greenbrook clinics in Q3 2025, marking a 25% increase on an adjusted pro forma basis compared to Q3 2024 [1][11] - Neuronetics' President and CEO, Keith J. Sullivan, announced his intention to retire effective June 30, 2026, with a search for his successor already underway [1][4] Financial Performance - Total revenues for Q3 2025 were $37.3 million, a 101% increase from $18.5 million in Q3 2024, driven primarily by the acquisition of Greenbrook TMS [7][8] - U.S. revenue increased by 102% to $36.2 million, while international revenue rose by 73% to $1.0 million compared to Q3 2024 [8] - The gross margin for Q3 2025 was 45.9%, down from 75.6% in Q3 2024, mainly due to the inclusion of Greenbrook's clinic business [11] Operational Highlights - The company shipped 40 NeuroStar Advanced Therapy Systems, generating $3.5 million in revenue, a 15% decrease from $4.1 million in Q3 2024 [9][10] - U.S. treatment session revenue was $10.5 million, down 21% from $13.3 million in Q3 2024, primarily due to the absence of $2.2 million in revenue from Greenbrook [10][11] - Neuronetics achieved a milestone of over 229,429 global patients treated with 8.2 million treatment sessions [7] Cash Management and Funding - As of September 30, 2025, the company held $34.5 million in total cash, an increase from $19.5 million at the end of 2024, with cash used in operations amounting to $0.8 million [14][15] - Neuronetics secured an additional $10 million in funding under its debt agreement with Perceptive Credit Holdings IV, LP, and extended its minimum liquidity requirement to September 2026 [15][16] Business Outlook - For Q4 2025, the company expects total worldwide revenue between $40 million and $43 million, and for the full year 2025, revenue is projected to be between $147 million and $150 million [18][19] - The company anticipates gross margin for the full year 2025 to be between 47% and 49%, with total operating expenses expected to be between $100 million and $105 million [19][20] - Neuronetics aims for positive cash flow from operations in Q4 2025, projecting a range of $2 million positive to $2 million negative [20]

Core Viewpoint - Neuronetics, Inc. has entered into a three-year exclusive agreement with Elite DNA Behavioral Health to provide transcranial magnetic stimulation (TMS) devices and patient support services across Elite DNA's 30+ locations, aiming to enhance patient access to advanced mental health treatments [1][2][3] Company Overview - Neuronetics, Inc. focuses on developing products that improve the quality of life for patients with neurohealth disorders and is a leader in neuroscience, particularly in TMS therapy [5][6] - Elite DNA Behavioral Health, founded in 2013, is one of Florida's largest mental health networks, providing accessible mental health care through over 30 locations [4] Partnership Details - The collaboration will utilize Neuronetics' Greenbrook platform to enhance operational and patient-support services for Elite DNA, allowing their team to concentrate on patient experience [2][3] - The partnership aims to operationalize strategic values from Neuronetics' Greenbrook acquisition and serves as a model for future collaborations with other organizations [2] Treatment and Services - NeuroStar Advanced Therapy, a non-invasive TMS treatment, has delivered over 7.6 million treatments and is backed by extensive clinical data, making it the leading TMS treatment for major depressive disorder (MDD) in adults [5][6] - Greenbrook treatment centers also provide SPRAVATO (esketamine) Nasal Spray for treatment-resistant depression, having administered over 1.8 million treatments to more than 55,000 patients [6]

Company Overview - Neuronetics and Greenbrook have combined to leverage scale and capabilities for mental health treatment[17] - The combined company has treated 221,376 unique patients[18] and administered 7,912,427 treatments[19] - The company reported $129 million in annual revenue for 2024 (pro forma adjusted)[19] Market and Opportunity - The total available market is 293 million U S adults and adolescents suffering from depression, depression with anxiety, and OCD[33,34] - Approximately 8 million patients are poorly served by antidepressant medication[34] - Better Me Program (BMP) clinics treat 33 times more patients than non-BMP clinics[57,58] Financial Performance and Guidance - Q2 2025 revenue was $381 million, a 132% increase from Q2 2024[90] - The company projects revenue between $149 million and $155 million for FY 2025, representing a 15% to 19% pro forma year-over-year growth[85] - The company anticipates achieving positive cash flow from operations in Q4 2025[85]

Core Insights - Neuronetics, Inc. reported total revenue of $38.1 million for the second quarter of 2025, reflecting an 18% adjusted pro forma revenue growth and a 132% increase compared to the same quarter in 2024 [1][6][5] - The company achieved record revenue of $23.0 million from Greenbrook clinics during the quarter, contributing significantly to the overall revenue growth [1][6] - Cash used in operations was reduced to $3.5 million, outperforming the guidance of under $5 million [1][4] Financial Performance - Total revenues for the three months ended June 30, 2025, were $38.1 million, up from $16.5 million in the same period of 2024, primarily due to the acquisition of Greenbrook [5][6] - U.S. clinic revenue was $23.0 million, while international revenue increased by 41% to $452,000 [5][7] - Gross margin decreased to 46.6% from 74.0% year-over-year, mainly due to the inclusion of Greenbrook's clinic business [10] Operational Highlights - The company shipped 41 NeuroStar Advanced Therapy Systems, generating $3.5 million in revenue, although this represented a 13% decrease compared to the previous year [8][6] - U.S. treatment session revenue was $10.8 million, an 8% decrease year-over-year, but a 13% increase on a pro forma basis [9][6] - Neuronetics treated over 209,000 global patients with 7.6 million treatment sessions [6] Management and Strategic Developments - Steven Pfanstiel was appointed as the new Chief Financial Officer, bringing over 20 years of healthcare experience [16] - The company secured an additional $10 million in funding from Perceptive Advisors LLC, extending its liquidity requirements [14] - Neuronetics expects total worldwide revenue for the third quarter of 2025 to be between $37.0 million and $39.0 million, and for the full year 2025, between $149.0 million and $155.0 million [17][18] Future Outlook - The company anticipates gross margin improvement in the second half of 2025, expecting it to be between 48% and 50% [18] - Total operating expenses for 2025 are now projected to be between $100.0 million and $105.0 million, reflecting the integration of Greenbrook [19] - Neuronetics expects to achieve positive cash flow from operations in the fourth quarter of 2025 [20]

Core Insights - Neuronetics, Inc. has published significant findings demonstrating the effectiveness of NeuroStar TMS in treating adolescents and young adults with depression, as reported in a leading medical journal [1][2] Company Overview - Neuronetics is a medical technology company focused on improving the quality of life for patients with neurohealth disorders through innovative products [4] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for major depressive disorder (MDD) and other mental health conditions across the United States [4] Treatment Efficacy - The study based on the NeuroStar TrakStar Clinical Database involved 1,283 patients, with approximately 70% reporting clinically meaningful improvement in depression symptoms, while less than 1% experienced worsening [2][3] - The results for adolescents and young adults align with previous findings in adult populations, indicating a strong correlation between the number of treatment sessions completed and clinical improvement [2] Market Opportunity - With one in five adolescents experiencing major depressive disorder and limited FDA-approved medications available, NeuroStar TMS presents a significant opportunity to provide a safe and effective treatment option for this demographic [3] - Since receiving FDA clearance as an add-on therapy for adolescents aged 15-21 in March 2024, there has been over a one-third increase in the number of adolescents treated with NeuroStar [2]

Company Leadership Transition - Steven Pfanstiel has been appointed as the new Chief Financial Officer of Neuronetics, effective July 15, 2025, replacing Steve Furlong, who will retire on March 31, 2026 [2][3] - Steve Furlong will continue to serve as Senior Advisor to the CEO during the transition period to ensure operational continuity [2][3] Executive Background - Steven Pfanstiel brings over two decades of healthcare experience, having previously served as CFO and COO at Marinus Pharmaceuticals, where he was instrumental in the launch of the flagship product, Ztalmy [3][4] - Pfanstiel has held senior financial roles at various high-growth healthcare companies, including Lifescan and Optinose, and has experience at Johnson & Johnson across multiple product categories [3][4] Strategic Vision and Growth - Neuronetics aims to expand access to mental health treatments and deliver sustainable growth, leveraging Pfanstiel's expertise in financial leadership and growth strategies [3][4] - The company is focused on integrating Greenbrook operations and achieving positive cash flow in the third quarter of 2025, marking a significant operational milestone [5] Stock Incentives - As part of his employment agreement, Pfanstiel received an inducement grant of 400,000 restricted stock units, with specific vesting schedules tied to his continued employment [4] Company Performance and Market Position - Neuronetics reaffirms its guidance for the second quarter and full year 2025, driven by successful integration efforts and key growth drivers [5] - The company operates Greenbrook TMS treatment centers across the U.S., offering NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD) [6][7]

Core Insights - NeuroStar, a Silver Sponsor at the 13th Annual Clinical TMS Society (CTMSS) Meeting, is committed to clinical innovation and excellence in mental health care [1][2] - The company will present two significant poster presentations based on the TrakStar data set, which is the largest real-world outcomes database in TMS [2][3] - NeuroStar aims to optimize TMS efficacy and expand its use into new populations and protocols, reinforcing its leadership in the psychiatric community [3] Company Updates - NeuroStar will present a retrospective analysis comparing clinical outcomes between its proprietary Figure-8 coil and Brainsway's H-coil in treating depression [2] - The company is evaluating personalized qEEG-informed protocols for TMS therapy, demonstrating operational feasibility with the NeuroStar TMS System [4] - NeuroStar has delivered over 7.4 million treatments and operates Greenbrook TMS centers across the U.S. for treating Major Depressive Disorder (MDD) and other mental health disorders [6] Event Participation - The CTMSS Meeting will take place from June 11-14 in San Diego, CA, where NeuroStar will also participate in the PULSES Course for TMS providers [2] - Presentations will include data on elderly adults (age 70 and older) with MDD treated with TMS, and a retrospective analysis from 200 Greenbrook centers [7]

Company Overview - Neuronetics, Inc. is a commercial stage medical technology and healthcare company focused on transforming patient lives through neurohealth therapies [1] - The company operates the NeuroStar Advanced Therapy System, a non-drug, noninvasive treatment for major depressive disorder (MDD) and other neurohealth conditions [5][6] Market Position - Neuronetics is set to join the Russell 3000® Index and the Russell 2000® Index effective June 30, 2025, which is a significant milestone for the company [1][4] - The Russell indexes are widely utilized by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against them [2] Strategic Vision - The inclusion in the Russell indexes validates Neuronetics' strategic vision and operational execution, enhancing visibility among institutional investors [4] - The company aims to expand access to innovative mental health treatments through an integrated approach, combining NeuroStar technology with a growing clinic network [4] Treatment Impact - NeuroStar Advanced Therapy has delivered over 7.4 million treatments and is backed by the largest clinical data set for TMS treatment for depression [5] - Greenbrook treatment centers have provided more than 1.8 million treatments to over 55,000 patients suffering from depression [5]